Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5825568 | Clinical Therapeutics | 2014 | 39 Pages |
Abstract
Although our analysis was limited by the absence of head-to-head trials, based on the indirect comparison data available, our model projects that apixaban may be a cost-effective alternative to dabigatran 150 mg BID, dabigatran 110 mg BID, and rivaroxaban 20 mg once daily for stroke prevention in AF patients from the perspective of the United Kingdom National Health Services.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Gregory Y.H. Lip, Thitima Kongnakorn, Hemant Phatak, Andreas Kuznik, Tereza Lanitis, Larry Z. Liu, Uchenna Iloeje, Luis Hernandez, Paul Dorian,